Eli Lilly CEO David Ricks explains Q1 earnings miss, lowered forecast

Eli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investmentПодробнее

Eli Lilly CEO David Ricks breaks down Q1 earnings, obesity drug trial resultsПодробнее

Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipelineПодробнее

Eli Lilly CEO David Ricks on Q3 earnings beat, Mounjaro strengthПодробнее

Eli Lilly CEO David Ricks on positive Alzheimer's drug trial dataПодробнее

Eli Lilly CEO reacts to Q3 earnings miss, provides pipeline updateПодробнее

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsПодробнее

Eli Lilly CEO: Alzheimer's drug trial shows slowed disease progression by 40-60% in early patientsПодробнее

Watch CNBC's full interview with Eli Lilly CEO David RicksПодробнее

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more productПодробнее

Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David RicksПодробнее

Eli Lilly CEO Ricks on Sales Forecast, Alzheimer's DrugПодробнее

Facing Forward: Eli Lilly CEO David Ricks on COVID-19 treatmentsПодробнее

Coronavirus: Eli Lilly CEO David Ricks on development of therapiesПодробнее

Eli Lilly CEO David Ricks explains how the company’s new covid-19 therapies help patientsПодробнее

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicineПодробнее

Eli Lilly CEO on Q2 earnings and core business performanceПодробнее

Eli Lilly CEO Reiterates 5% Revenue Growth TargetПодробнее